590 related articles for article (PubMed ID: 26031368)
1. Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.
Sclafani F; Peckitt C; Cunningham D; Tait D; Giralt J; Glimelius B; Keränen SR; Bateman A; Hickish T; Tabernero J; Thomas J; Brown G; Oates J; Chau I
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):303-12. PubMed ID: 26031368
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
3. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Kripp M; Wieneke J; Kienle P; Welzel G; Brade J; Horisberger K; Wenz F; Post S; Gencer D; Hofmann WK; Hofheinz RD
Eur J Surg Oncol; 2012 Jun; 38(6):472-7. PubMed ID: 22349986
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis.
Ozgen Z; Ozden S; Atasoy BM; Ozyurt H; Gencosmanoglu R; Imeryuz N
Radiat Oncol; 2015 Aug; 10():168. PubMed ID: 26264590
[TBL] [Abstract][Full Text] [Related]
5. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
6. Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis.
Couwenberg AM; Burbach JPM; van Grevenstein WMU; Smits AB; Consten ECJ; Schiphorst AHW; Wijffels NAT; Heikens JT; Intven MPW; Verkooijen HM
Clin Colorectal Cancer; 2018 Sep; 17(3):e499-e512. PubMed ID: 29678514
[TBL] [Abstract][Full Text] [Related]
7. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
9. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.
Hess V; Winterhalder R; von Moos R; Widmer L; Stocker P; Jermann M; Herrmann R; Koeberle D
Clin Colorectal Cancer; 2017 Sep; 16(3):240-245. PubMed ID: 27687815
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Ye W; Shi L; Qian L; Sun Y; Sun X
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in non-early rectal cancer treated by neoadjuvant radio-chemotherapy and endoluminal loco-regional resection (ELRR) by transanal endoscopic microsurgery (TEM) versus laparoscopic total mesorectal excision.
D'Ambrosio G; Paganini AM; Balla A; Quaresima S; Ursi P; Bruzzone P; Picchetto A; Mattei FI; Lezoche E
Surg Endosc; 2016 Feb; 30(2):504-511. PubMed ID: 26045097
[TBL] [Abstract][Full Text] [Related]
17. Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial.
Kogler P; DeVries AF; Eisterer W; Thaler J; Sölkner L; Öfner D;
Strahlenther Onkol; 2018 Jan; 194(1):41-49. PubMed ID: 29127435
[TBL] [Abstract][Full Text] [Related]
18. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.
Urso E; Serpentini S; Pucciarelli S; De Salvo GL; Friso ML; Fabris G; Lonardi S; Ferraro B; Bruttocao A; Aschele C; Nitti D
Eur J Surg Oncol; 2006 Dec; 32(10):1201-8. PubMed ID: 16872799
[TBL] [Abstract][Full Text] [Related]
19. [Quality of life of patients with locally advanced rectal cancer after neoadjuvant therapy and sphincter-preserving surgery].
Shi WK; Li YH; Qiu XY; Xiao Y; Zhou JL; Wu B; Lin GL
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Apr; 25(4):348-356. PubMed ID: 35461204
[No Abstract] [Full Text] [Related]
20. Impaired continence function five years after intensified chemoradiation in patients with locally advanced rectal cancer.
Horisberger K; Rothenhoefer S; Kripp M; Hofheinz RD; Post S; Kienle P
Eur J Surg Oncol; 2014 Feb; 40(2):227-33. PubMed ID: 24378010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
